Suppr超能文献

对ClinicalTrials.gov上发布的知情同意书中关键信息部分的特征描述。

Characterization of key information sections in informed consent forms posted on ClinicalTrials.gov.

作者信息

Gelinas Luke, Morrell Walker, Tse Tony, Glazier Ava, Zarin Deborah A, Bierer Barbara E

机构信息

Advarra Inc., Columbia, MD, USA.

Division of Global Health Equity, Department of Medicine, Multi-Regional Clinical Trials Center of Brigham and Women's Hospital and Harvard, Brigham and Women's Hospital, Boston, MA, USA.

出版信息

J Clin Transl Sci. 2023 Aug 14;7(1):e185. doi: 10.1017/cts.2023.605. eCollection 2023.

Abstract

INTRODUCTION

Recent revisions to the US Federal Common Rule governing human studies funded or conducted by the federal government require the provision of a "concise and focused" key information (KI) section in informed consent forms (ICFs). We performed a systematic study to characterize KI sections of ICFs for federally funded trials available on ClinicalTrials.gov.

METHODS

We downloaded ICFs posted on ClinicalTrials.gov for treatment trials initiated on or after the revised Common Rule effective date. Trial records ( = 102) were assessed by intervention type, study phase, recruitment status, and enrollment size. The ICFs and their KI sections, if present, were characterized by page length, word count, readability, topic, and formatting elements.

RESULTS

Of the 102 trial records, 76 had identifiable KI sections that were, on average, 10% of the total length of full ICF documents. KI readability grade level was not notably different from other sections of ICFs. Most KI sections were distinguished by section headers and included lists but contained few other formatting elements. Most KI sections included a subset of topics consistent with the basic elements of informed consent specified in the Common Rule.

CONCLUSION

Many of the KI sections in the study sample aligned with practices suggested in the preamble to the revised Common Rule. Further, our results suggest that some KI sections were tailored in study-specific ways. Nevertheless, guidelines on how to write concise and comprehensible KI sections would improve the utility and readability of KI sections.

摘要

引言

美国联邦政府对由其资助或开展的人体研究的《联邦通用规则》最近进行了修订,要求在知情同意书(ICF)中提供一个“简洁且重点突出”的关键信息(KI)部分。我们进行了一项系统研究,以描述ClinicalTrials.gov上可获取的联邦资助试验的ICF中KI部分的特征。

方法

我们下载了ClinicalTrials.gov上发布的、在修订后的《通用规则》生效日期或之后启动的治疗试验的ICF。通过干预类型、研究阶段、招募状态和入组规模对试验记录(n = 102)进行评估。对ICF及其KI部分(如果有),从页面长度、单词数、可读性、主题和格式元素等方面进行特征描述。

结果

在102份试验记录中,76份有可识别的KI部分,这些部分平均占完整ICF文件总长度的10%。KI部分的可读性年级水平与ICF的其他部分没有显著差异。大多数KI部分以章节标题区分,包含列表,但几乎没有其他格式元素。大多数KI部分包含的主题子集与《通用规则》中规定的知情同意基本要素一致。

结论

研究样本中的许多KI部分与修订后的《通用规则》前言中建议的做法一致。此外,我们的结果表明,一些KI部分是以特定研究的方式进行调整的。然而,关于如何撰写简洁且易懂的KI部分的指南将提高KI部分的实用性和可读性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/69dc/10514692/341c9dfa8efe/S2059866123006052_fig2.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验